Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
Phase of Trial: Phase III
Latest Information Update: 12 Oct 2019
Price : $35 *
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 10-valent vaccine conjugate; Pneumococcal vaccine conjugate
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Pharmacodynamics; Registrational
- Sponsors sanofi pasteur
- 11 Sep 2019 Last checked against European Clinical Trials Database record.
- 27 Mar 2019 Planned End Date changed from 1 Aug 2021 to 1 Mar 2022.
- 27 Mar 2019 Planned primary completion date changed from 1 Aug 2021 to 1 Mar 2022.